UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of | (Commission File Number) | (IRS Employer Identification No.) |
incorporation) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(b) Departure of Executive Vice President, Chief Medical Officer
On December 27, 2021, Judith Ng-Cashin separated as Executive Vice President, Chief Medical Officer of Eagle Pharmaceuticals, Inc., or the Company. The Company intends to initiate the search for a replacement immediately.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 27, 2021 | EAGLE PHARMACEUTICALS, INC. | |
By: | /s/ Scott Tarriff | |
Scott Tarriff | ||
Chief Executive Officer |
Cover |
Dec. 27, 2021 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Dec. 27, 2021 |
Entity File Number | 001-36306 |
Entity Registrant Name | Eagle Pharmaceuticals, Inc. |
Entity Central Index Key | 0000827871 |
Entity Tax Identification Number | 20-8179278 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 50 Tice Boulevard |
Entity Address, Address Line Two | Suite 315 |
Entity Address, City or Town | Woodcliff Lake |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07677 |
City Area Code | 201 |
Local Phone Number | 326-5300 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock (par value $0.001 per share) |
Trading Symbol | EGRX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G
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end